Ultragenyx Pharmaceutical | RARE - Net Income

Stock Price
24.49
Daily Change
-0.20 -0.81%
Monthly
8.65%
Yearly
-46.51%
Q1 Forecast
23.33

Ultragenyx Pharmaceutical reported $-180.41M in Net Income for its fiscal quarter ending in September of 2025.





Net Income Change Date
Acadia Pharmaceuticals USD 71.78M 45.11M Sep/2025
Agios Pharmaceuticals USD -103.43M 8.59M Sep/2025
Alnylam Pharmaceuticals USD 251.08M 317.36M Sep/2025
BioMarin Pharmaceutical USD -30.74M 271.28M Sep/2025
Insmed USD -370.02M 48.34M Sep/2025
Ionis Pharmaceuticals USD -128.61M 252.16M Sep/2025
Kyowa Hakko Kirin JPY 16.28B 6.13B Sep/2025
MacroGenics USD 16.82M 53.07M Sep/2025
Moderna USD -200M 625M Sep/2025
Neurocrine Biosciences USD 209.5M 102M Sep/2025
PTC Therapeutics USD 15.9M 80.75M Sep/2025
Regeneron Pharmaceuticals USD 844.6M 615.4M Dec/2025
Sarepta Therapeutics USD -179.95M 376.84M Sep/2025
Ultragenyx Pharmaceutical USD -180.41M 65.46M Sep/2025
Vertex Pharmaceuticals USD 1.08B 50M Sep/2025